NVDA
NVIDIA
-- 140.140 TSLA
Tesla
-- 394.360 PLTR
Palantir
-- 69.990 AUR
Aurora Innovation
-- 8.390 FUBO
FuboTV
-- 5.460 
Watching!
$Nuvation Bio (NUVB.US)$ Reported Saturday, Nuvation Bio Revealed Findings From The Crucial Phase 2 TRUST-I Trial Of Their Experimental ROS1 Inhibitor, Taletrectinib At The ASCO 2024
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study
Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years
TRUST-I is one of two registrational Phase 2 studies evaluating taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study
Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years
TRUST-I is one of two registrational Phase 2 studies evaluating taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
MARKET-TEST-DUMMY : watching too